Fig. 4: Protection by a 10-1074 HEC gel during repeated vaginal SHIV162P3 cell-associated challenges. | Nature Communications

Fig. 4: Protection by a 10-1074 HEC gel during repeated vaginal SHIV162P3 cell-associated challenges.

From: Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure

Fig. 4: Protection by a 10-1074 HEC gel during repeated vaginal SHIV162P3 cell-associated challenges.

A Follow-up of plasma vRNA load from macaques treated with the placebo gel (n = 6, control group, pink symbols) or with the 10-1074 gel (n = 6, treated group, blue symbols) and intravaginally exposed to 107 SHIV162P3-infected splenocytes. The gray area indicates the eight weeks of challenges. The dotted line indicates the limit of quantification (LOQ = 111 copies/mL) for the viral load assay performed. Group colors are consistent throughout the manuscript. B The number of animals remaining uninfected is plotted against the number of SHIV162P3 cell-associated viral challenges. The Kaplan-Meier survival curves are significantly different in the placebo gel control group (pink curve) compared to the 10-1074 gel-treated group (blue curve) (p = 0.0227; Log-rank (Mantel-Cox) test). C SIV Gag DNA copy number detected in inguinal lymph nodes from the twelve macaques is reported for animals with detectable viremia. D SIV Gag DNA copies number detected in PBMC collected during the first 43 weeks of the study. The dotted line indicates the assay’s quantification limit (LOQ = 138 copies/106 cells). CM = cynomolgus macaque. Source data are provided as a Source Data file.

Back to article page